MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Maria Grazia Rodriquenz; Giandomenico Roviello; Alberto D'Angelo; Daniele Lavacchi; Franco Roviello; Karol Polom

doi:10.3390/jcm9051427

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

J Clin Med. 2020 May 11;9(5):1427. doi: 10.3390/jcm9051427.

Authors

Maria Grazia Rodriquenz¹, Giandomenico Roviello², Alberto D'Angelo³, Daniele Lavacchi⁴, Franco Roviello⁵, Karol Polom⁶

Affiliations

¹ Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, via Padre Pio 1, 85028 Rionero, Vulture (PZ), Italy.
² Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139 Florence, Italy.
³ Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK.
⁴ Azienda Ospedaliera Careggi University Hospital of Florence and University of Florence, 50134 Florence, Italy.
⁵ Department of Medical, Surgical and Neuro Sciences, Section of Surgery, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy.
⁶ Department of Surgical Oncology, Gdansk Medical University, 80-210 Gdansk, Poland.

Abstract

Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

Keywords: EBV; MSI; immunotherapy; molecular subtypes.

Publication types

Review